CCIA
VRDN icon

Campbell & Co Investment Adviser’s Viridian Therapeutics VRDN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,157
Closed -$590K – 1378
2026
Q1 		$590K Sell
30,157
-17,695
-37% -$526K 0.03% 692
2025
Q4 		$1.49M Buy
47,852
+21,537
+82% +$591K 0.07% 429
2025
Q3 		$568K Buy
+26,315
New +$475K 0.04% 671

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Campbell & Co Investment Adviser's VRDN Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 30,157 shares — an estimated $590K sold.

Campbell & Co Investment Adviser first reported a position in VRDN in Q3 2025 and held it in 3 quarters. The position peaked at $1.49M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 30,157 Viridian Therapeutics shares in Q2 2026, an estimated $590K.
  • Campbell & Co Investment Adviser first reported a position in Viridian Therapeutics in Q3 2025 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Viridian Therapeutics position peaked at $1.49M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.